AR103427A1 - Vacuna contra la fiebre aftosa - Google Patents

Vacuna contra la fiebre aftosa

Info

Publication number
AR103427A1
AR103427A1 ARP160100102A ARP160100102A AR103427A1 AR 103427 A1 AR103427 A1 AR 103427A1 AR P160100102 A ARP160100102 A AR P160100102A AR P160100102 A ARP160100102 A AR P160100102A AR 103427 A1 AR103427 A1 AR 103427A1
Authority
AR
Argentina
Prior art keywords
foot
mouth disease
immunogenic composition
composition
immunostimulatory oligonucleotide
Prior art date
Application number
ARP160100102A
Other languages
English (en)
Inventor
Elizabeth Rieder Aida
William Krug Peter
Leandro Rodriguez Luis
Gerard Gay Cyril
Alan Jackson James
Morgan Hardman John
Joseph Dominowski Paul
Original Assignee
Zoetis Services Llc
Usda-Ars Plum Island Animal Disease Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc, Usda-Ars Plum Island Animal Disease Center filed Critical Zoetis Services Llc
Publication of AR103427A1 publication Critical patent/AR103427A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Composiciones para la prevención de la fiebre aftosa, que comprenden un componente antigénico en la cantidad equivalente a 0,5 - 20 mg del virus de la fiebre aftosa y un componente adyuvante que comprende aceite, un oligonucleótido inmunoestimulante y un vehículo policatiónico. También procedimientos de uso de la composición, así como los procedimientos de reducir la persistencia de la fiebre aftosa. Reivindicación 2: La composición inmunogénica de la reivindicación 1, caracterizada porque: a) dicho componente adyuvante comprende el polímero policatiónico, b) dicho polímero policatiónico es dextrano dietilaminoetil (DEAE). Reivindicación 3: La composición inmunogénica de la reivindicación 1 o la reivindicación 2, caracterizada porque el oligonucleótido inmunoestimulante comprende CpG. Reivindicación 4: La composición inmunogénica de una cualquiera de las reivindicaciones 1 - 3, caracterizada porque el oligonucleótido inmunoestimulante comprende al menos 15 nucleótidos contiguos de la SEC ID Nº 8. Reivindicación 11: La composición inmunogénica de una cualquiera de las reivindicaciones 1 - 10, caracterizada porque dicha composición del virus de la fiebre aftosa es una preparación de la cepa Cruzeiro del virus de la fiebre aftosa.
ARP160100102A 2015-01-16 2016-01-15 Vacuna contra la fiebre aftosa AR103427A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562104314P 2015-01-16 2015-01-16

Publications (1)

Publication Number Publication Date
AR103427A1 true AR103427A1 (es) 2017-05-10

Family

ID=55361946

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100102A AR103427A1 (es) 2015-01-16 2016-01-15 Vacuna contra la fiebre aftosa

Country Status (27)

Country Link
US (3) US10478487B2 (es)
EP (2) EP4248992A3 (es)
JP (4) JP7113620B2 (es)
KR (3) KR20170097116A (es)
CN (3) CN115317600A (es)
AR (1) AR103427A1 (es)
AU (2) AU2016206525A1 (es)
BR (1) BR112017015288A2 (es)
CA (1) CA2973828C (es)
CO (1) CO2017007057A2 (es)
DK (1) DK3244920T3 (es)
ES (1) ES2950822T3 (es)
FI (1) FI3244920T3 (es)
HK (1) HK1246659A1 (es)
HR (1) HRP20230752T1 (es)
HU (1) HUE063288T2 (es)
IL (1) IL253137B2 (es)
LT (1) LT3244920T (es)
MX (2) MX2017009306A (es)
PH (1) PH12017501257A1 (es)
PL (1) PL3244920T3 (es)
PT (1) PT3244920T (es)
RU (1) RU2698305C2 (es)
SG (1) SG11201705737RA (es)
SI (1) SI3244920T1 (es)
WO (1) WO2016115456A1 (es)
ZA (1) ZA201704596B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201705737RA (en) * 2015-01-16 2017-08-30 Zoetis Services Llc Foot-and-mouth disease vaccine
CN106474466B (zh) * 2016-12-07 2018-04-13 申联生物医药（上海）股份有限公司 一种口蹄疫疫苗的制备方法
AU2018390817A1 (en) * 2017-12-20 2020-06-25 Zoetis Services Llc Vaccines against Hendra and Nipah virus infection
KR102285977B1 (ko) 2019-03-15 2021-08-05 대한민국 오일 에멀젼과 병용 투여 가능한 면역증강용 보조물질 및 이를 포함하는 구제역 백신 조성물
CN112516325B (zh) * 2019-09-18 2023-12-08 洛阳赛威生物科技有限公司 一种稳定的口蹄疫疫苗组合物及其应用
WO2021242879A1 (en) * 2020-05-27 2021-12-02 The United States Of America, As Represented By The Secretary Of Agriculture Live attenuated strains of foot and mouth disease modified by deoptimization and uses thereof

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR228580A1 (es) 1980-11-25 1983-03-30 Torre Jose Leonardo Procedimiento para inactivar el virus de la fiebre aftosa
US4732971A (en) 1985-06-03 1988-03-22 Eli Lilly And Company Synthetic vaccines for foot and mouth disease
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
ES2037072T3 (es) 1986-12-19 1993-06-16 Duphar International Research B.V Suspension coadyuvante estabilizada que comprende bromuro de dimetil-dioctadecil-amonio.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
RU1615918C (ru) * 1989-05-22 1995-07-09 Всероссийский научно-исследовательский институт защиты животных Адъювант
ZA936095B (en) 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6764682B1 (en) 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
US5824316A (en) 1996-05-24 1998-10-20 The United States Of America As Represented By The Secretary Of Agriculture Leader-proteinase deleted foot-and-mouth disease viruses and their use as vaccines
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ATE441432T1 (de) 1997-03-10 2009-09-15 Ottawa Hospital Res Inst Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien
AU751433B2 (en) 1997-04-30 2002-08-15 Merieux Oravax Anti-(helicobacter) vaccine composition for use by the subdiaphragmatic systemic route, and combined mucosal/parenteral immunization method
DE69841002D1 (de) 1997-05-14 2009-09-03 Univ British Columbia Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
CA2291483C (en) 1997-06-06 2012-09-18 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
IL139646A0 (en) 1998-05-14 2002-02-10 Coley Pharm Group Inc Methods for regulating hematopoiesis using cpg-oligonucleotides
EP1733735B1 (en) 1998-05-22 2017-03-22 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
JP4620251B2 (ja) 1998-08-10 2011-01-26 アンチジェニックス・インコーポレイテッド Ｃｐｇおよびサポニンアジュバントの組成物並びにその方法
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
EP1146887A4 (en) * 1999-01-12 2003-05-07 Univ Princeton GLYCOPEPTIDE ANTIBIOTICS CONTAINING DESMETHYLVANCOSAMINE RESIDUE, COMBINATORIAL BANKS AND METHODS OF MAKING SAME
CA2363141C (en) 1999-02-26 2010-04-06 Chiron Corporation Microemulsions with adsorbed macromolecules and microparticles
JP4932086B2 (ja) 1999-04-08 2012-05-16 インターセル ユーエスエイ、インコーポレイテッド 経皮的免疫のための乾燥製剤
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
BRPI0010612B8 (pt) 1999-04-19 2021-05-25 Smithkline Beecham Biologicals S A vacinas
EP1177439B1 (en) 1999-04-29 2004-09-08 Coley Pharmaceutical GmbH Screening for immunostimulatory dna functional modifiers
ATE378348T1 (de) 2000-01-14 2007-11-15 Us Health Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
AU3108001A (en) 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
JP5025871B2 (ja) 2000-02-21 2012-09-12 エイチ．リュンドベック エイ／エス アミロイドの新規なダウン−レギュレート方法
CA2407942A1 (en) 2000-05-01 2001-11-08 Hybridon, Inc. Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
EP1985702A3 (en) 2000-12-08 2010-08-18 Coley Pharmaceutical GmbH CPG-like nucleic acids and methods of use thereof
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
US7713942B2 (en) 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
WO2002080648A2 (en) 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
US7105495B2 (en) 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
CA2447793A1 (en) 2001-05-21 2002-11-28 Intercell Ag Immunostimulatory oligodeoxynucleic molecules
JP2005509591A (ja) 2001-06-15 2005-04-14 リバファーム・インコーポレイテッド ヌクレオシドワクチンアジュバント
DK1474067T4 (en) 2001-07-02 2017-10-16 Zoetis Services Llc One-dose vaccination with I Mycoplasma Hyopneumoniae / I
EP1521592A2 (en) 2001-07-02 2005-04-13 Pfizer Products Inc. Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
EP1501359A4 (en) 2001-08-03 2007-04-18 Celldex Therapeutics Inc COMPOSITIONS CONTAINING IMMUNOSTIMULATING OLIGONUCLEOTIDES AND USES THEREOF FOR AMPLIFYING IMMUNOTHERAPIES INDIRECTLY DISENGAGED BY THE FC RECEPTOR
US20030133988A1 (en) 2001-08-07 2003-07-17 Fearon Karen L. Immunomodulatory compositions, formulations, and methods for use thereof
US20030138434A1 (en) 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
SG177000A1 (en) 2001-08-17 2012-01-30 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
PL368826A1 (en) 2001-08-28 2005-04-04 Pfizer Products Inc. Mycoplasma bovis challenge model, methods for administering m. bovis and methods for inducing pneumonic lung lesions
DK1450856T3 (da) 2001-09-14 2010-05-31 Cytos Biotechnology Ag Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse
US7514415B2 (en) 2002-08-01 2009-04-07 The United States Of America As Represented By The Department Of Health And Human Services Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides
US20030119774A1 (en) 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
EP1434602B1 (en) 2001-10-06 2014-12-17 Merial Limited CpG plus oil in water emulsion as adjuvant system for truncated bovine herpesvirus-1 glycoprotein D
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
RU2212895C2 (ru) 2001-11-01 2003-09-27 Федеральное государственное учреждение Всероссийский научно-исследовательский институт защиты животных Вакцина против ящура типа о и способ ее изготовления
WO2003039595A2 (en) 2001-11-07 2003-05-15 Inex Pharmaceuticals Corporation Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
US20050250716A1 (en) 2001-12-07 2005-11-10 Intercell Ag Immunostimulatory oligodeoxynucleotides
US7741297B2 (en) 2002-02-04 2010-06-22 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
AU2003217580A1 (en) 2002-02-19 2003-09-09 Syntherica Corporation Surrogate antibodies and methods of preparation and use thereof
CA2478932A1 (en) * 2002-03-29 2003-10-16 Merck & Co., Inc. Large scale methods of producing adenovirus and adenovirus seed stocks
EP3006043B1 (en) 2002-04-04 2019-05-29 Zoetis Belgium S.A. Immunostimulatory g,u-containing oligoribonucleotides
AU2003262379A1 (en) 2002-04-16 2003-11-03 Auburn University TRANSIENT AND/OR PERMANENT MODIFICATION OF SEXUAL BEHAVIOR AND/OR FERTILITY USING RECOMBINANT CHIMERIC GnRH
KR20050009697A (ko) 2002-04-22 2005-01-25 바이오니취 라이프 사이언시즈 인코포레이티드 올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도
KR100456681B1 (ko) 2002-05-22 2004-11-10 주식회사 대웅 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
WO2003100040A1 (en) 2002-05-28 2003-12-04 Merck Patent Gmbh A method for generating antigen-presenting cells
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
SE0201701D0 (sv) 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
US20040009949A1 (en) 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
RU2220744C1 (ru) 2002-07-01 2004-01-10 Федеральное государственное учреждение Всероссийский научно-исследовательский институт защиты животных Вакцина против ящура типа азия-1 и способ ее изготовления
EP1565406A4 (en) 2002-11-05 2008-07-23 James Hardie Int Finance Bv PROCESS AND APPARATUS FOR PRODUCING CALCIUM SILICATE HYDRATE
JP2006515024A (ja) 2003-01-29 2006-05-18 ファイザー・プロダクツ・インク Ｂｏｒｄｅｔｅｌｌａｂｒｏｎｃｈｉｓｅｐｔｉｃａに対するイヌワクチン
ZA200507562B (en) * 2003-03-26 2006-11-29 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
PT1613346E (pt) 2003-04-04 2013-01-29 Pah Usa 15 Llc Emulsões óleo-em-água microfluidificadas e composições de vacinas
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
DK1742659T3 (da) 2004-04-05 2013-06-03 Zoetis P Llc Mikrofluidiserede olie-i-vand-emulsioner og vaccinesammensætninger
WO2006078943A2 (en) * 2005-01-19 2006-07-27 Micro Beef Technologies, Ltd. Method and system for tracking and managing animals and/or food products
CA2604488A1 (en) 2005-04-07 2006-10-12 Pharmacia & Upjohn Company Llc Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines
CN101495139A (zh) * 2005-11-10 2009-07-29 迪娃解决方案股份有限公司 鉴别治疗组合物
AU2007209104B2 (en) 2006-01-26 2010-04-08 Zoetis Services Llc Novel glycolipid adjuvant compositions
US20080038295A1 (en) * 2006-04-13 2008-02-14 Regents Of The University Of Michigan Compositions and methods for orthopox virus vaccination
MX2009003398A (es) * 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
US20080292663A1 (en) 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
CL2008001806A1 (es) 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
NZ727616A (en) * 2008-06-27 2018-06-29 Zoetis Services Llc Novel adjuvant compositions
PT2402032T (pt) 2009-02-27 2019-11-19 Toray Industries Composição imunogénica
US20110014232A1 (en) * 2009-07-16 2011-01-20 Agricultural Research Council Chimeric foot and mouth disease viruses
PL2475384T3 (pl) * 2009-09-10 2017-02-28 Merial, Inc. Nowe formulacje szczepionek obejmujące adiuwanty zawierające saponiny
US8846057B2 (en) 2010-01-19 2014-09-30 The United States Of America, As Represented By The Secretary Of Agriculture Recombinant live attenuated foot-and-mouth disease (FMD) vaccine containing mutations in the L protein coding region
US8765141B2 (en) 2010-07-01 2014-07-01 The United States Of America, As Represented By The Secretary Of Agriculture Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host
EP3858381A1 (en) 2011-02-04 2021-08-04 Zoetis Services LLC Immunogenic bordetella bronchiseptica compositions
EP3777886A1 (en) * 2012-11-16 2021-02-17 United Biomedical Inc. Synthetic peptide-based emergency vaccine against foot and mouth disease (fmd)
CN103083663B (zh) * 2013-02-04 2014-12-10 江苏省农业科学院 一种免疫增强剂、灭活疫苗及其制备方法
WO2015042423A2 (en) * 2013-09-19 2015-03-26 Zoetis Llc Vaccine
SG11201705737RA (en) * 2015-01-16 2017-08-30 Zoetis Services Llc Foot-and-mouth disease vaccine
US10035841B2 (en) 2016-01-29 2018-07-31 The Texas A&M University System Monoclonal antibody against novel epitopes of foot-and-mouth disease virus protein 3ABC and uses thereof
US10172933B2 (en) 2016-10-31 2019-01-08 The United States Of America, As Represented By The Secretary Of Agriculture Mosaic vaccines for serotype a foot-and-mouth disease virus

Also Published As

Publication number Publication date
JP2021001205A (ja) 2021-01-07
RU2698305C2 (ru) 2019-08-26
KR20220044395A (ko) 2022-04-07
IL253137B2 (en) 2024-03-01
KR20170097116A (ko) 2017-08-25
HRP20230752T1 (hr) 2023-10-27
BR112017015288A2 (pt) 2018-01-16
WO2016115456A1 (en) 2016-07-21
JP7361867B2 (ja) 2023-10-16
US10478487B2 (en) 2019-11-19
IL253137A0 (en) 2017-08-31
US20180264101A1 (en) 2018-09-20
KR102508719B1 (ko) 2023-03-09
LT3244920T (lt) 2023-08-25
EP4248992A3 (en) 2023-12-27
JP2018502166A (ja) 2018-01-25
RU2017124186A3 (es) 2019-02-18
JP7232225B2 (ja) 2023-03-02
RU2017124186A (ru) 2019-02-18
CN107106674A (zh) 2017-08-29
AU2016206525A1 (en) 2017-07-13
AU2021257973A1 (en) 2021-11-25
PL3244920T3 (pl) 2023-09-25
ZA201704596B (en) 2018-05-30
DK3244920T3 (da) 2023-06-26
MX2017009306A (es) 2017-11-08
SG11201705737RA (en) 2017-08-30
CO2017007057A2 (es) 2017-10-31
PT3244920T (pt) 2023-07-28
HK1246659A1 (zh) 2018-09-14
SI3244920T1 (sl) 2023-09-29
CN115317600A (zh) 2022-11-11
KR20200068759A (ko) 2020-06-15
US20200078456A1 (en) 2020-03-12
HUE063288T2 (hu) 2024-01-28
EP4248992A2 (en) 2023-09-27
PH12017501257A1 (en) 2017-10-30
US20220088173A1 (en) 2022-03-24
JP2022130383A (ja) 2022-09-06
EP3244920B1 (en) 2023-06-07
ES2950822T3 (es) 2023-10-13
KR102382773B1 (ko) 2022-04-04
FI3244920T3 (fi) 2023-08-04
JP2023012507A (ja) 2023-01-25
CA2973828A1 (en) 2016-07-21
US11865171B2 (en) 2024-01-09
IL253137B1 (en) 2023-11-01
US10967058B2 (en) 2021-04-06
EP3244920A1 (en) 2017-11-22
MX2021015972A (es) 2022-02-10
CN114699518A (zh) 2022-07-05
CA2973828C (en) 2023-09-19
JP7113620B2 (ja) 2022-08-05

Similar Documents

Publication Publication Date Title
AR103427A1 (es) Vacuna contra la fiebre aftosa
CL2016000650A1 (es) Composicion de vacuna que comprende un antigeno y una formulacion coadyuvante, que comprende al menos el 50 % v/v de una fase oleosa, monofosforil-lipido a (mpl-a) o un analogo del mismo y un oligonucleotido inmunoestimulate; y uso de la composición de vacuna para preparar un medicamento.
CO2017011245A2 (es) Conjugados proteína-polisacárido de estreptococo grupo b, métodos para producir conjugados, composiciones inmunógenas que comprenden conjugados y sus usos
EP4233898A3 (en) Influenza mrna vaccines
CO6270337A2 (es) Vacuna viva avirulenta de mycoplama hyopneumoniae con adyuvante
AR069882A1 (es) Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e
CL2017001961A1 (es) Vacuna bivalente contra el virus de gripe porcina
PE20061287A1 (es) COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y EL ADYUVANTE TH-1
PE20151588A1 (es) Vacuna contra el virus del dengue
AR052625A1 (es) Nueva composicion
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
AR071917A1 (es) Vacunas contra la coccidiosis
AR106026A1 (es) Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos
PE20140871A1 (es) COMPOSICIONES Y METODOS DE VACUNA DEL VIRUS TIPO 1b DE DIARREA VIRAL BOVINA
PE20211545A1 (es) Dosis unitaria de vacuna contra el dengue y administracion de esta
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
CO6280408A2 (es) Vacuna de virus de la lengua azul y composiciones inmunogenicas procedimientos de uso y procedimeintos de la produccuion de la misma
PH12018501368A1 (en) M hyo multivalent vaccine and uses thereof
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
PE20170429A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
CO6361950A2 (es) Composiciones, vacunas y metodos del virus del herpes del ganado bovino -1
CO2019012289A2 (es) Obtención de una salmonela enteritidis tipo rugosa y sus modificaciones genéticas para uso como vacuna aviar
AR097029A1 (es) Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune